» Articles » PMID: 35673672

Molecular Analyses of Rosette-forming Glioneuronal Tumor of the Midbrain Tegmentum: A Report of Two Cases and a Review of the FGFR1 Status in Unusual Tumor Locations

Overview
Journal Surg Neurol Int
Specialty Neurology
Date 2022 Jun 8
PMID 35673672
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Rosette-forming glioneuronal tumor (RGNT) is a rare tumor that arises primarily in the posterior fossa, with molecular features of mutation. A previous study reported that brainstem RGNT accounts for only 2.7% cases; therefore, midbrain RGNT is infrequent.

Case Description: The authors encountered two cases of RGNT located in the midbrain tegmentum (Case 1: 23-year-old woman and Case 2: 18-year-old boy), both exhibiting similar cystic components with gadolinium-enhanced cyst walls on preoperative magnetic resonance imaging, surgically resected through the occipital transtentorial approach. Histological findings in both cases comprised two characteristic architectures of neurocytic and glial components, typical of RGNT. Molecular assessment revealed no mutation in the initial specimen, but revealed K656E mutation in the recurrent specimen in Case 1 and showed no mutation but showed C228T mutation in Case 2. Neither case revealed K27, G34, or K27 mutations. DNA methylation-based classification (molecularneuropathology.org) categorized both cases as RGNT, whose calibrated scores were 0.99 and 0.47 in Cases 1 and 2, respectively.

Conclusion: Midbrain tegmentum RGNTs exhibited typical histological features but varied statuses with mutation. RGNT in rare locations may carry different molecular alterations than those in other common locations, such as the posterior fossa.

Citing Articles

The Clinical and Molecular Landscape of Rosette-Forming Glioneuronal Tumors.

Yang Z, Zhang X Biomedicines. 2024; 12(10).

PMID: 39457636 PMC: 11505073. DOI: 10.3390/biomedicines12102325.

References
1.
Solis O, Mehta R, Lai A, Mehta R, Farchoukh L, Green R . Rosette-forming glioneuronal tumor: a pineal region case with IDH1 and IDH2 mutation analyses and literature review of 43 cases. J Neurooncol. 2010; 102(3):477-84. PMC: 3089723. DOI: 10.1007/s11060-010-0335-1. View

2.
Sieg E, Payne R, Langan S, Specht C . Case Report: A Rosette-forming Glioneuronal Tumor in the Tectal Plate in a Patient with Neurofibromatosis Type I. Cureus. 2016; 8(11):e857. PMC: 5133136. DOI: 10.7759/cureus.857. View

3.
Hsu C, Kwan G, Lau Q, Bhuta S . Rosette-forming glioneuronal tumour: imaging features, histopathological correlation and a comprehensive review of literature. Br J Neurosurg. 2012; 26(5):668-73. DOI: 10.3109/02688697.2012.655808. View

4.
Arita H, Yamasaki K, Matsushita Y, Nakamura T, Shimokawa A, Takami H . A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas. Acta Neuropathol Commun. 2016; 4(1):79. PMC: 4977715. DOI: 10.1186/s40478-016-0351-2. View

5.
Kikuchi Z, Shibahara I, Yamaki T, Yoshioka E, Shofuda T, Ohe R . promoter mutation associated with multifocal phenotype and poor prognosis in patients with wild-type glioblastoma. Neurooncol Adv. 2020; 2(1):vdaa114. PMC: 7586143. DOI: 10.1093/noajnl/vdaa114. View